Breast Cancer: Open Trials
ABCSG 18 ZA
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study to Determine the Treatment Effect of Denosumab in Subjects With Non-Metastatic Breast Cancer Receiving Aromatase Inhibitor Therapy/ Zoledronic Acid (ZA) Substudy
ABCSG 18 ZA was developed as an additional protocol to assess the effects of a single intravenous ZA administration on bone density, fracture incidence, and bone turnover markers (CTX and osteocalcin) in a subset of ABCSG 18 patients after discontinuation of denosumab.
ABCSG 18 ZA details »
ABCSG 22R-QoL
A questionnaire investigating long-term quality of life (QoL) outcome including sexual health and fertility concerns based survey among breast cancer patients registered in ABCSG 22R.
ABCSG 22R-QoL details »
ABCSG 45
A prospective, open, randomized, phase II study of carboplatin/ olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive homologous recombination deficiency (HRD) status
ABCSG 45 details »
ABCSG 47 / IMpassion030
A phase III, multicenter, randomized, open-label study comparing atezolizumab (anti PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer ABCSG 47 / IMpassion030 details »
ABCSG 49 / POLAR
A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer
Palbociclib for HR positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (POLAR)
ABCSG 49 / POLAR details »
ABCSG 50/BRCA-P
A randomized, double-blind, placebo-controlled, multi-center, international phase 3 study to determine the preventive effect of denosumab on breast cancer in women carrying a BRCA1 germline mutation.
ABCSG 50/BRCA-P details »
ABCSG 51/ AURORA
Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer
ABCSG 51/ AURORA details »
ABCSG 52 / ATHENE
An open-label, two-arm, randomized, single-stage phase II study of ATezolizumab in combination with dual HER2 blockade plus epirubicin as NEoadjuvant therapy for HER2-positive early breast cancer.
ABCSG 52 / ATHENE details »